BioNanoTech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2017, BioNanoTech is a private, pre-revenue platform company developing a proprietary resin technology for protein and antibody purification. The platform is positioned as a tool to address critical bottlenecks in biologics manufacturing, potentially accelerating drug discovery and reducing production waste. Led by CEO Dr. Onyema Osuagwu, the company targets biopharma partners seeking to improve purity, yield, and efficiency in their pipelines. Its value proposition centers on turning previously discarded research materials into viable drug candidates.

Drug DeliveryNanotechnologySmall Molecules

Technology Platform

Proprietary nanotechnology-based resin platform for single-step purification of proteins and antibodies across a wide size range, aimed at streamlining biologics manufacturing.

Opportunities

The massive and growing biologics market creates a significant need for more efficient purification technologies.

BioNanoTech's platform, if validated, could unlock value from shelved drug candidates and reduce manufacturing costs for partners, creating a compelling value proposition.

The company operates in the tools sector, which can be less risky than drug development and may lead to partnerships or acquisition interest from larger life science tools companies.

Risk Factors

The company's core technology claims lack public, third-party validation, posing a major adoption risk.

It faces intense competition from established, well-capitalized giants in the chromatography resin market.

As a pre-revenue, private startup, it also carries significant funding and execution risks in scaling its nanotechnology from lab to commercial production.

Competitive Landscape

BioNanoTech competes in the large and established chromatography resin market, dominated by multinational corporations like Cytiva (Cytiva CaptivA, MabSelect), Thermo Fisher Scientific, and Merck KGaA. Its differentiation is based on a claim of broader size-range purification in a single step, a niche not explicitly addressed by current market leaders. Success requires displacing incumbent solutions deeply integrated into existing biomanufacturing workflows.

More companies in United States →